Current landscape of frontline and relapsed follicular lymphoma trials

Treatment for follicular lymphoma (FL) has rapidly advanced in recent years, with a broad array of novel agents demonstrating promising results, particularly in the relapsed or refractory (R/R) setting. Key emerging therapies include chimeric antigen receptor T-cell therapy, bispecific antibodies, and various targeted therapies, many of which are currently being evaluated in frontline and earlier lines of relapses, against standard of care. These new therapeutic approaches offer the potential for improved patient outcomes, but their integration into clinical practice presents challenges such as determining the optimal sequencing and selection of treatment, balancing unique benefits, toxicities, and treatment burdens, and overall therapeutic goals, especially in the R/R space. Moreover, the heterogeneous nature of FL, coupled with its indolent and long-term course, necessitates a personalized approach to therapy that considers the individual patient's needs and preferences. This approach ensures that the most suitable treatment is chosen, balancing efficacy with quality-of-life considerations. In this review, we provide a comprehensive summary and in-depth discussion of ongoing phase 3 clinical trials both at frontline and R/R. We explore various aspects of these trials, including their study designs, limitations, and potential clinical applicability. In addition, we examine how these trials may shape future treatment practices and address the broader challenges surrounding the concept of achieving a cure in FL. By critically analyzing the evolving landscape of FL treatment, this review aims to offer valuable insights into how these new therapeutic strategies might affect patient management, and the future direction of FL clinical studies.